Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF

BACKGROUND: Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a common co-morbidity in heart failure with preserved ejection fraction (HFpEF)....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cardiovasc Diabetol
Päätekijät: Bode, David, Semmler, Lukas, Wakula, Paulina, Hegemann, Niklas, Primessnig, Uwe, Beindorff, Nicola, Powell, David, Dahmen, Raphael, Ruetten, Hartmut, Oeing, Christian, Alogna, Alessio, Messroghli, Daniel, Pieske, Burkert M., Heinzel, Frank R., Hohendanner, Felix
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2021
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7792219/
https://ncbi.nlm.nih.gov/pubmed/33413413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01208-z
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia